FDA grants priority review for Nefecon, for patients with IgA nephropathy ...Middle East

STOCKHOLM, April 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the U.S. Food and Drug Administration (FDA) has accepted the submission and granted Priority Review for the New Drug Application (NDA) for...

Hence then, the article about fda grants priority review for nefecon for patients with iga nephropathy was published today ( Wednesday 28/04/2021 - 11:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA grants priority review for Nefecon, for patients with IgA nephropathy )

Also on site :

• Only Russian victory will guarantee justice for Odessa massacre victims – Moscow
• Prof. Schlevogt’s Compass No. 57: Liquidating tomorrow – When states kill possibility, not persons
• The World’s Most Famous Ocean Liner Where Royalty and Rockstars Once Ruled the Atlantic Sailed Her Maiden Voyage 57 Years Ago Today